Skip to main content
. 2024 Jul 9;15:5763. doi: 10.1038/s41467-024-49915-5

Fig. 4. Survival association with early, on-therapy ctKRAS dynamics by variant for PRINCE cohort.

Fig. 4

Shown is the association with one-year survival (alive or dead at one year) for therapy-naive PRINCE patients with any detected baseline ctKRAS mutation as measured by A changes in ctKRAS variant allele fraction (VAF) from baseline to week 8 on therapy (n = 37), or B ctKRAS clearance at week 8 on therapy for G12D only (left) and G12V only (right). Shown in C is Kaplan-Meyer analysis dichotomized by ctKRAS clearance vs no clearance and association with overall survival for G12D only (left), and G12V only (right). Results for progression-free survival shown in D. Among the 39 PRINCE patients with both a baseline and week 8 plasma obtained, 2 had insufficient follow-up to determine 1-year survival and were thus excluded from the results shown in A, B. Mann–Whitney test (two-sided) used for comparisons in A. Fishers exact test (two-sided) used in B. Cox regression hazard ratios (HR) and 95% confidence intervals (CI) are shown with log-rank p-values for C, D. Source data are provided as a Source Data file.